[Medicine heaven and earth] focusing on the new progress of special procurement of anticancer drugs in 24 regions, many regions require the lowest price in the country. This week, 579 pharmaceutical companies were named, 2 pharmaceutical companies were fined for inferior drugs, and 5 pharmaceutical companies were accepted GMP

Local governments have made new policies and focused on the progress of special procurement of anticancer drugs in 24 regions The new pricing rules are different According to the requirements of the notice on carrying out provincial special centralized procurement of anticancer drugs (health insurance Fa [2018] No 4) issued by the state health insurance bureau and the National Health Commission, each province has successively issued specific plans After sorting out, we know that there have been 24 policies on special procurement of anticancer drugs Let's take a look at the implementation of typical 10 provinces (municipalities directly under the central government, autonomous regions) 2018.09.11 Sichuan Province - key policy points of the notice on declaration of tax reduction and price reduction for special centralized procurement of anti-cancer drugs in Sichuan Province in 2018: there are 67 drugs declared for price reduction in this batch, including 42 injections, 14 tablets, 1 dispersible tablet, 9 capsules / capsules and 1 implant For the online products that do not implement the national tax reduction and price reduction policy and do not submit the price adjustment application within the specified time, they are temporarily included in the scope of Online Limited purchase in accordance with the relevant requirements of the implementation plan; for the anti-cancer drugs that refuse to reduce the price, the Sichuan provincial drug purchase supervision platform will timely report to the society, and the relevant departments of the province will submit them to the National Health Insurance Bureau for research and treatment September 10, 2018 Anhui Province - key policy points of the notice on carrying out provincial special centralized procurement of anticancer drugs: the procurement catalogue involves the anticancer drug manufacturers in the notice on value added tax policy of anticancer drugs (CS [2018] No 47) issued the list of anticancer drugs (the first batch) According to the price issued by the provincial drug purchase platform (except for the drugs negotiated successfully in this volume purchase negotiation), the medical institutions of the whole province implement zero margin sales, and the tax reduction and price reduction part shall be included in the price reduction range of each volume purchase consortium The price of anticancer drugs is the lowest in China According to the order of the purchase amount of provincial drug procurement platform in the first half of 2018, for the anticancer drugs ranking top 80% of the total purchase amount of anticancer drugs, refer to the first price of "two ticket system" and the actual transaction price of volume purchase of drugs from provincial hospitals and the largest comprehensive hospitals at the municipal level 2018.09.07 Shandong Province - key policy points of the document on special centralized procurement of anticancer drugs for medical institutions in Shandong Province (Draft for comments): the lowest price in China will be implemented for the procurement of anticancer drugs For the product specifications of 3 or more declared production enterprises, the competitive quotation of the production enterprises shall be adopted Drugs passing the consistency evaluation shall not be higher than the minimum purchase price adjusted by each province according to relevant regulations In the purchase of medical institutions, the products with the lowest quotation of each quotation group shall be selected preferentially In principle, at least one of the products with the lowest quotation of each quotation group of corresponding drugs shall be included in the purchase and use scope of the institution If the price of a product is not higher than 2% of the price of the lowest quoted product of the same group, it shall be deemed as the lowest quoted product For the drugs that only one or two manufacturers have declared and have not been connected to the provincial drug centralized purchase platform or have not been connected to the network but have not purchased in the past year, the manufacturers shall quote at the lowest purchase price not higher than the current provincial minimum purchase price of their respective drugs in each Province, which shall be included in the direct network 2018.09.05 Hubei Province - key policy points of the notice on special procurement of anticancer drugs for public medical institutions in the province: this special procurement includes all anticancer drugs in the online directory of the province The manufacturer must promise that the online price is not higher than the quoted price / online price in other provincial centralized procurement 2018.09.05 Fujian Province - key policy points of notice on special centralized purchase of anticancer drugs: drugs meeting the application conditions of anticancer drug purchase catalogue are grouped according to the document (2017) No 16 of minmedicare office and dynamic adjustment rules For the drugs with only exclusive declaration in the same group, on the basis of not higher than the current national minimum purchase price of the product, three rounds of man-machine dialogue negotiation shall be conducted by comprehensively referring to the purchase price of surrounding countries and regions, customs port price, product price reduction after tax reduction and reference price of medical insurance negotiation; for the drugs with two or more declarations in the same group, according to the medical insurance office of Fujian Province [2017] No 16 document and dynamic adjustment rules and other relevant provisions, on the basis of not higher than the current national minimum purchase price of the products declared by the enterprise, make three rounds of quotation with comprehensive reference to the purchase price of overseas surrounding countries and regions, customs port price, product price reduction after tax reduction and the lowest quotation of the same group In addition, if the price difference between each round of quotation and products within the group number is more than 30%, a warning will be given August 31, 2018 Jiangsu Province - key points of the policy of the implementation plan for special centralized procurement of anticancer drugs in Jiangsu Province: there are 65 kinds of Jiangsu anticancer drugs bargaining procurement catalogue and 13 kinds of filing procurement catalogue Enterprises are required to promise that the sales price in Jiangsu will not be higher than that in other provinces (cities, autonomous regions) August 31, 2018 Beijing - key policy points of the notice on printing and distributing the implementation plan for the special centralized purchase of anticancer drugs by public medical institutions in Beijing: support the hospital alliance composed of tumor hospitals and large-scale general hospitals, select varieties, link quantity and price, carry out volume negotiation with enterprises, and further reduce the space for drug prices 2018.08.30 Hebei Province - key points of the policy of the implementation plan of special centralized purchase of anticancer drugs: in principle, the number of special purchase varieties shall be no less than 70% of the actual use of drugs in the previous year to prepare a purchase plan, purchase with quantity, and exchange price for quantity The drugs listed in the special centralized purchase list of anticancer drugs can be directly linked to the Internet In principle, the price quoted by the pharmaceutical enterprises involved in the purchase of anticancer drugs shall not be higher than the actual purchase price of Beijing and Tianjin August 30, 2018 Shanghai - key policy points of the notice on special centralized purchase of anticancer drugs in this city: the special purchase of anticancer drugs includes the drugs negotiated by the state and the anticancer drugs listed in the list of drugs in short supply in Shanghai In purchasing other medical insurance drugs According to the situation of tax reduction, the production enterprise shall take the initiative to adjust the price to the municipal pharmacy office for filing In principle, the filing price shall meet the following conditions at the same time: first, it shall not be higher than the purchase price of 15 provinces and cities (specifically refers to the purchase price being implemented on the provincial drug purchase platforms of Beijing, Tianjin, Jiangsu, Zhejiang, Guangdong, Chongqing, Anhui, Fujian, Jiangxi, Shandong, Henan, Hebei, Liaoning, Hubei and Hunan) Second, compared with the original purchase price in this city, there is a decrease 2018.08.13 Jiangxi Province - key policy points of the implementation plan for special centralized procurement of anticancer drugs in Jiangxi Province in 2018 (Draft for comments): Products with 3 or more enterprises applying for bidding shall be included in the open bidding procurement of double envelope system; products with less than 3 enterprises applying for bidding and products with less than 3 enterprises after the bidding group is divided into bidding groups according to the open bidding procurement of double envelope system shall be subject to price negotiation at the provincial level The enterprise shall quote according to the market share of medical institutions in the whole province and the production cost of the enterprise Medical institutions shall not purchase drugs that are not awarded the bid, give priority to the selection of basic drugs, pass the consistency evaluation of generic drugs, conform to the clinical pathway, include drugs into major disease guarantee, major new drug creation special projects, and major public health projects, and make a good connection with the medical insurance reimbursement policy In addition, 14 provinces, including Shanxi, Inner Mongolia, Liaoning, Jilin, Heilongjiang, Hunan, Guangxi, Hainan, Guizhou, Gansu, Qinghai, Ningxia, Xinjiang and Shaanxi, have issued the inter provincial alliance special procurement announcement for imported anticancer drugs The key policy points are as follows: 1 Based on 103 kinds of anticancer drug preparations, 14 kinds of drugs that have been reduced in tax and price in national negotiations on anticancer drugs have been eliminated, and two PD-1 inhibitors (nafulizumab and pabolizumab) have been added 2 The members of the alliance shall jointly determine a province to be the bargaining organization Each province shall send three corresponding chief physicians or pharmacists as bargaining representatives to participate in the bargaining work of the alliance The bargaining group shall randomly select bargaining products and production enterprises for face-to-face bargaining 3 For products with unsuccessful price negotiation and products without special reasons, members of the alliance will suspend the network connection, and the manufacturer and members of the alliance will renegotiate the price On September 11, 579 local pharmaceutical enterprises were named, and Anhui Provincial Food and Drug Administration announced the supervision and inspection information of drug circulation in August 2018 According to statistics, in drug retail enterprises and drug wholesale enterprises, 572 enterprises have been found problems (individual enterprises repeat due to different inspection time) Among them, 15 pharmaceutical companies were put on file for investigation; 1 was warned and ordered to rectify; 556 were ordered to rectify (including rectification within a time limit, immediate rectification, on-site rectification, etc.) On September 13, Fujian Longyan and Guangdong Zhongshan drug regulatory bureaus released the latest administrative punishment information According to statistics, there are seven drug companies "on the list", including three selling inferior drugs, two selling fake drugs, one producing inferior drugs, and one purchasing drugs from enterprises without drug production and operation qualification Two 2 pharmaceutical companies fined for inferior drugs Two cases of administrative punishments have been issued by Leshan drug regulatory bureau in Sichuan Province, one is the case of Leshan Kangfa Pharmaceutical Co., Ltd producing the inferior medicine cicada molt, with a total fine of 111489.75 yuan; the other is the case of Leshan Dongfang health medicine retail chain Co., Ltd selling the inferior medicine Belladonna and other two kinds of medicines in Jadeite store, and the case of purchasing the Chinese medicine pieces by the enterprises without production and operation qualifications, with a total of 111489.75 yuan RMB 55479.41 will be calculated as penalty On September 14, Shaanxi public resources trading center issued the announcement on the withdrawal of GMP certificate involving the centralized procurement platform of pharmaceutical equipment in August 2018 This time, 5 enterprises including Guangxi Haihai sunshine Pharmaceutical Co., Ltd (formerly Beihai sunshine Pharmaceutical Co., Ltd.) and Guangxi Hongbo Pharmaceutical Co., Ltd were involved At the same time, the relevant departments decided to take measures to suspend the network of 48 drugs of the above-mentioned pharmaceutical enterprises according to law Sampling inspection of local drugs: on September 10, 25 batches of unqualified drugs, Henan Xinyang Drug Administration issued the notice on 4 batches of unqualified drugs in sampling inspection (issue 1, 2018) At the same time, relevant departments have taken necessary risk control measures such as sealing up, detaining and suspending the sale of unqualified drugs in random inspection, and investigated and punished the source units of the inspected drugs according to law On September 13, Sichuan food and Drug Administration issued the Sichuan drug quality announcement (the seventh issue in 2018), which announced 21 batches of unqualified drugs found in drug sampling II Rectification: five types of drugs in the retail industry were strictly inspected On September 11, the drug regulatory bureau of Ganzi Prefecture, Sichuan Province issued the notice on the centralized rectification of drug retail enterprises According to the announcement, through special rectification, the circulation channels of drugs will be further standardized, drug traceability will be strengthened, outstanding problems and illegal acts in the circulation of drugs will be seriously rectified and investigated, fake and inferior drugs will be prevented from flowing into legal channels, and the safety and effectiveness of public drug use will be guaranteed Among them, the bureau decided to focus on the treatment of five categories of drugs, namely Chinese herbal pieces, compound preparations containing special drugs, drugs for the treatment of diabetes, cardiovascular diseases, and painkillers and analgesics Information source: yaozhi.com, national health and Health Commission, sepilan, local medical station, Yaoxiang, medical mobile newspaper, Sohu and other statements: This paper only represents the author, not the position of yaozhi.com, welcome to exchange and supplement in the message area; if you need to reprint, please be sure to indicate the author and source of the article.